The Clorox Company (NYSE:CLX) Shares Purchased by Creative Planning

Creative Planning increased its holdings in shares of The Clorox Company (NYSE:CLX) by 7.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,089 shares of the company’s stock after acquiring an additional 1,996 shares during the quarter. Creative Planning’s holdings in Clorox were worth $4,739,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Clorox by 0.3% during the first quarter. Vanguard Group Inc. now owns 15,277,580 shares of the company’s stock worth $2,339,150,000 after acquiring an additional 48,632 shares during the last quarter. Nuance Investments LLC boosted its position in Clorox by 150.6% during the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock worth $218,035,000 after acquiring an additional 960,094 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Clorox by 1,715.5% in the 2nd quarter. Van ECK Associates Corp now owns 1,461,207 shares of the company’s stock valued at $199,411,000 after purchasing an additional 1,380,724 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Clorox by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock valued at $131,200,000 after purchasing an additional 120,716 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Clorox by 26.5% in the 1st quarter. Acadian Asset Management LLC now owns 882,526 shares of the company’s stock valued at $135,099,000 after purchasing an additional 184,847 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Price Performance

Shares of CLX opened at $158.92 on Friday. The Clorox Company has a fifty-two week low of $114.68 and a fifty-two week high of $169.09. The firm’s 50 day moving average price is $160.25 and its 200 day moving average price is $145.43. The company has a market cap of $19.74 billion, a P/E ratio of 82.34, a PEG ratio of 3.19 and a beta of 0.41. The company has a quick ratio of 0.63, a current ratio of 1.03 and a debt-to-equity ratio of 5.04.

Clorox (NYSE:CLX) last announced its earnings results on Thursday, August 1st. The company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.28. Clorox had a net margin of 3.95% and a return on equity of 281.12%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. On average, research analysts forecast that The Clorox Company will post 6.64 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd will be paid a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 3.07%. The ex-dividend date is Wednesday, October 23rd. Clorox’s payout ratio is currently 252.85%.

Insider Buying and Selling

In related news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at $2,229,719.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.51% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

CLX has been the topic of several recent analyst reports. Barclays boosted their target price on shares of Clorox from $130.00 to $137.00 and gave the company an “underweight” rating in a report on Friday, October 11th. DA Davidson reiterated a “neutral” rating and issued a $153.00 target price on shares of Clorox in a report on Friday, September 6th. JPMorgan Chase & Co. boosted their target price on shares of Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a report on Friday, October 11th. Evercore ISI decreased their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a report on Monday, October 14th. Finally, TD Cowen assumed coverage on shares of Clorox in a report on Tuesday, July 23rd. They issued a “sell” rating and a $122.00 target price on the stock. Six research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $150.14.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.